An update on the safety of apremilast for the treatment of plaque psoriasis

References

• Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012 Mar;26(Suppl 2):3–11.
   PubMed Web of Science ®Google Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii18–23; discussion ii24–5.
   PubMedGoogle Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007 Jul;157(1):68–73.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005 Nov 15;10(22):1503–1519.
   PubMed Web of Science ®Google Scholar
• Otezla [package insert]. Summit, NJ: Celgene Corporation; 2014 [cited 2019 Nov 15. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acf6751-827d-11e2-9e96-0800200c9a66
   Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019 Nov 14;381(20):1918–1928.
   PubMed Web of Science ®Google Scholar
• Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015 Jun;20(2):209–220. Epub 2015 Feb 3.
   PubMed Web of Science ®Google Scholar
• Zambon AC, Zhang L, Minovitsky S, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA. 2005;102(24):8561–8566.
   PubMed Web of Science ®Google Scholar
• Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113–118.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583–1590. Epub 2012 Jan 10.
   PubMed Web of Science ®Google Scholar
• Wright LC, Seybold J, Robichaud A, et al. Phosphodiesterase expression in human epithelial cells. Am J Physiol. 1998 Oct;275(4):L694–700.
   PubMedGoogle Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–864.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
   PubMed Web of Science ®Google Scholar
• Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol. 2007;157(1):213.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol. 2019 Apr 10;5(3):141–150. eCollection 2019 Jul.
   PubMedGoogle Scholar
• Bangsgaard N, Rørbye C, Skov L. Treating psoriasis during pregnancy: safety and efficacy of treatments. Am J Clin Dermatol. 2015 Oct;16(5):389–398.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387–1399. Epub 2015 Nov 7.
   PubMed Web of Science ®Google Scholar
• Dozier L, Bartos G, Kerdel F. Apremilast and psoriasis in the real world: a retrospective case series. J Am Acad Dermatol. 2019 Oct 8. pii: S0190-9622(19)32889-0. [Epub ahead of print]. DOI:10.1016/j.jaad.2019.10.009.
   PubMedGoogle Scholar
• Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2019 Aug 10. pii: S0190-9622(19)32566-6. [Epub ahead of print]. DOI:10.1016/j.jaad.2019.08.019.
   Google Scholar
• Lee EB, Amin M, Wu JJ. Drug survival of apremilast in patients treated for psoriasis in a real-world setting. J Am Acad Dermatol. 2018 Oct;79(4):760–761. Epub 2018 Mar 26. No abstract available.
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Komine M, Kamiya K, et al. Drug survival of apremilast in a real-world setting. J Dermatol. 2019 Jul;46(7):615–617. Epub 2019 Jun 10.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the international psoriasis council. J Am Acad Dermatol. 2019 Aug 16. pii: S0190-9622(19)32573-3. [Epub ahead of print]. DOI: 10.1016/j.jaad.2019.08.026.
   Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015 Mar;42(3):479–488. Epub 2015 Jan 15.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016 Sep;43(9):1724–1734. Epub 2016 Jul 15.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017 Dec;22(12):CD011535.
   Google Scholar
• Armstrong AW, Betts KA, Sundaram M, et al. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Acad Dermatol. 2016 Oct;75(4):740–746. Epub 2016 Jul 28.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Pelletier CL, Wilson KL, et al. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019 Jan;8(1):45–54. Epub 2018 Nov 2.
   PubMed Web of Science ®Google Scholar